No patients with a BRAF-mutant tumor responded to cetuximab, whereas objective responses were observed in 17% patients with wild-type BRAF. Patients with BRAF mutation also had a shorter PFS, regardless of whether cetuximab was administered in the second or third or higher lines. Here, BRAF is linked to neoplasm.